Stay updated with breaking news from Eric Benevich. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Neurocrine Biosciences (NASDAQ:NBIX – Get Rating) had its target price cut by Barclays from $131.00 to $125.00 in a research note issued to investors on Thursday, The Fly reports. Several other research analysts have also recently issued reports on NBIX. StockNews.com initiated coverage on Neurocrine Biosciences in a report on Thursday, March 16th. They issued […]
Neurocrine Biosciences (NASDAQ:NBIX – Get Rating) had its target price decreased by Mizuho from $116.00 to $111.00 in a research note released on Thursday, The Fly reports. Other research analysts also recently issued reports about the company. Evercore ISI upgraded Neurocrine Biosciences from an in-line rating to an outperform rating and set a $130.00 target […]
Shell Asset Management Co. cut its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Rating) by 15.2% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 4,533 shares of the company’s stock after selling 811 shares during the quarter. Shell Asset Management Co.’s […]
Canandaigua National Corp trimmed its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Rating) by 8.3% during the 4th quarter, HoldingsChannel.com reports. The firm owned 1,735 shares of the company’s stock after selling 157 shares during the period. Canandaigua National Corp’s holdings in Neurocrine Biosciences were worth $207,000 as of its most recent filing with […]
Larson Financial Group LLC lifted its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Rating) by 20.2% in the fourth quarter, HoldingsChannel reports. The firm owned 2,331 shares of the company’s stock after purchasing an additional 391 shares during the period. Larson Financial Group LLC’s holdings in Neurocrine Biosciences were worth $278,000 at the end […]